Astellas Pharma Day

February 8, 2022 3:30 PM - 5:00 PM

MassBioHub, 700 Technology Square, 5th Floor Cambridge MA 02139

Add to Calendar 2/8/2022 3:30:00 PM 2/8/2022 5:00:00 PM Astellas Pharma Day Accelerate your biotech company, startup, or university’s innovation portfolio at our Astellas 2022 Pharma Day on February 8.

MassBio’s Pharma Days® are unparalleled opportunities for emerging innovators to learn from and connect with world-leading biopharmaceutical companies.

Connect on February 8 | Innovators with small molecule, gene therapy, mRNA, or cell therapy candidates or technology in the therapeutic areas listed below who are actively looking for licensing opportunities are encouraged to apply for a one-on-one virtual meeting with Astellas representatives. Astellas’ target therapeutic areas are:
•    Oncology
•    Immuno-Science
•    Mitochondria Biology
•    Regeneration/Reprogramming

Applications for one-on-one meetings can be found here, and must be submitted by January 7, 2022 at 12:00AM (midnight) ET.

Protection of intellectual property rights (ex. patents, trademarks, copyright, trade secrets, etc.) of your concept is your responsibility and your responsibility alone. Information you include in your application will be shared with State of Possible partners. Please note that these partners did NOT sign Non-Disclosure Agreements (NDAs). Therefore, you should not include any information in your application that you feel could be harmful to your company should that information be disclosed.

  MassBioHub, 700 Technology Square, 5th Floor Cambridge MA 02139
President, Astellas Institute for Regenerative Medicine
Dr. Masahide [Hide] Goto is President of the Astellas Institute for Regenerative Medicine (AIRM). He has 30 years’ experience as a researcher in molecular biology and as a leader for research teams across a wide variety of therapeutic areas, including metabolic and infectious disease, antibodies, nucleic acid medicine and gene therapy-related activities, ophthalmology, and otology. Dr. Goto joined Astellas as a researcher in molecular medicine in 1997 for Astellas predecessor Yamanouchi Pharmaceutical Co., Ltd. His prior roles at the company include Senior Director, Biologics, Modality Research Laboratory; Executive Director, Candidate Discovery Research Unit 3, Candidate Discovery Science Laboratory; and Executive Director, Eye & Ear Virtual Venture Unit. Dr. Goto holds a Ph.D. in Biotechnology from the Tokyo Institute of Technology and is the author of nearly 20 scientific papers.

Brought to you by